Meticulous Research®—a leading global market research company, published a research report titled, ‘Epigenetics Market by Offering (Kits, Reagents, Instruments, Software) Method (DNA Methylation, PCR, Chromatin Analysis, Histone, RNA Modification), Application (Oncology, Non-oncology) End User (Pharma, Academics, Hospitals) – Global Forecast to 2030.’
According to this latest publication from Meticulous Research®, the global epigenetics market is projected to reach $5.47 billion by 2030 at a CAGR of 15.7%. The growth of this market is driven by the rising incidence of chronic diseases due to growth in the aging population, the increasing prevalence of cancer, rising pharmaceutical R&D expenditures, the increasing focus on epigenetics in drug discovery & development, and the declining costs of genome sequencing. However, the lack of skilled professionals restrains the growth of this market.
The growing applications of epigenetics in non-oncology diseases and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the stakeholders in this market. However, standardization concerns associated with epigenetics procedures and the limited applications of epigenetics in toxicology are major challenges to market growth.
The key players operating in the global epigenetics market are Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), New England Biolabs (U.S.), Epigentek Group Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Active Motif (U.S.), and Zymo Research Corporation (U.S.).
Epigenetics Market: Future Outlook
The global epigenetics market is segmented by Offering [Kits & Reagents (Kits & Assays, Antibodies, Proteins & Enzymes, and Other Reagents), Services, Software], Method [ DNA Methylation (Bisulfite Conversion, High-resolution Melt (HRM) Analysis, Immunoprecipitation, Other DNA Methylation Methods), Histone Modification, RNA Modification, Polymerase Chain Reaction (PCR), Chromatin Analysis, Sonication, and Other Methods], Application [Oncology, Non-oncology], End User [Biotechnology & Pharmaceutical Companies, Academic & Research Institutes, and Hospitals & Diagnostic Laboratories]and Geography. The study also evaluates industry competitors and analyzes their market share at global and regional levels.
Among all the offerings studied in this report, in 2023, the kits & reagents segment is expected to account for the largest share of the epigenetics market. The kits & reagents segment is further segmented into kits & assays, antibodies, proteins & enzymes, and other reagents. In 2023, the kits & assays segment is expected to grow at the highest CAGR during the forecast period. Kits & assays are bundled components such as primers, antibodies, histones, controls, and proteins used to study epigenetics through chromatin analysis, DNA methylation, histone modification, and mi-RNA analysis, among other methods. They are available in panels, discs, cassettes, and cartridges. The repetitive use of kits & assays and the emergence of sequencing, mi-RNA, and real-time PCR technologies, which provide real-time results with high accuracy and shorter turnaround times, enhancing research and disease diagnosis drives the segment's growth.
Among all the methods studied in this report, in 2023, the DNA methylation segment is expected to account for the largest share of the market. DNA methylation is further segmented into bisulfite conversion, high-resolution melt (HRM) analysis, immunoprecipitation, and other DNA methylation methods. The high-melt resolution (HRM) analysis segment is projected to grow at the highest CAGR during the forecast period.
High-resolution melt (HRM) analysis is a qualitative analysis of a DNA fragment’s melt curve following PCR amplification. It is considered a next-generation application of amplicon melting analysis. These assays require a real-time PCR detection system with thermal stability, sensitivity, and HRM-dedicated software. Combining improved qPCR instrumentation and saturating DNA-binding dyes allows for identifying small variations in nucleic acid sequences through the controlled melting of double-stranded PCR amplicons. Such advanced PCR instruments coupled with HRM-compatible software enable the rapid analysis of the resulting data sets and the discrimination of DNA sequences based on their composition, length, GC content, or strand complementarity, leading to the segment's growth.
Among all the applications studied in this report, in 2023, the oncology segment is expected to account for the largest share of the market. This large segment share can be attributed to the high burden of cancer globally, supportive initiatives by the government and organizations for cancer, and advances in cancer research. Cancer can be genetic or adaptive depending on lifestyle, genetic factors, and secondary disorders.
Cancer is one of the leading causes of death globally. It is a prominent obstacle to improving life expectancy in every country. The exact cause of cancer is unknown in many types; hence, there is a high focus on cancer research to develop products for cancer management. Epigenetics helps differentiate the nuclear organization, DNA methylation, and histone modification patterns between cancer and normal cells. Several changes in cancer cells, such as lower histone post-translational modifications (methylation or acetylation), are associated with poor outcomes in prostate, lung, and kidney cancers. It is leading to the use of epigenetics in cancer diagnosis and treatment.
Among all end users studied in this report, in 2023, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the epigenetics market. The largest share of this segment is attributed to the rising demand for research-related products, the increasing incidence of chronic diseases, pharmaceutical & biotechnology companies’ rising R&D expenditures, technological advancements in epigenetics, and the introduction of new epigenetics products for chronic and rare diseases.
Among all regions studied in this report, Asia-Pacific is expected to grow at the highest CAGR during the forecast period. The highest CAGR of the region is attributed to government initiatives for genetic diseases, growing cancer incidence, rising geriatric population, rapid rise in the prevalence of chronic diseases, rising R&D spending, and increasing healthcare expenditure.
This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, and the Rest of Asia-Pacific), Latin America, and the Middle East & Africa.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5628
Key questions answered in the report-
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Dental Practice Management Software Market Worth $ 3.11 Billion by 2029Read More